Citations

Clear

499 citation(s) found for "Tracy, PB".

Gastrostomy tube placement increases the risk of ventriculoperitoneal shunt infection: a multiinstitutional study
Al‐Holou, Wajd N. , Wilson, Thomas J. , Ali, Zarina S. , Brennan, Ryan P., Bridges, Kelly J., Guivatchian, Tannaz, Habboub, Ghaith , Krishnaney, Ajit A., Snyder, Kendall, Than, Khoi D. , Snyder, Kendall A, Al-Holou, Wajd N , Lanzino, Giuseppe , Flanders, Tracy M. , Pandey, Aditya S

Mayo Clinic

Journal of Neurosurgery | February 27, 2019 | Volume: 131 | Issue: 4 | Pages: 1062-1067

10.3171/2018.5.jns18506 | PMID 30497165 Get It

OBJECTIVEGastrostomy tube placement can temporarily seed the peritoneal cavity with bacteria and thus theoretically increases the risk of shunt infection when the two procedures are performed contemporaneously. The authors hypothesized that gastrostomy tube placement would not increase the risk of ventriculoperitoneal shunt infection. The object of this study was to test this hypothesis by utilizing a large patient cohort combined from multiple institutions.METHODSA retrospective study of all adult patients admitted to five institutions with a diagnosis of aneurysmal subarachnoid hemorrhage between January 2005 and January 2015 was performed. The primary outcome of interest was ventriculoperitoneal shunt infection. Variables, including gastrostomy tube placement, were tested for their association with this outcome. Standard statistical methods were utilized.RESULTSThe overall cohort consisted of 432 patients, 47% of whom had undergone placement of a gastrostomy tube. The overall shunt infection rate was 9%. The only variable that predicted shunt infection was gastrostomy tube placement (p = 0.03, OR 2.09, 95% CI 1.07–4.08), which remained significant in the multivariate analysis (p = 0.04, OR 2.03, 95% CI 1.04–3.97). The greatest proportion of shunts that became infected had been placed more than 2 weeks (25%) and 1–2 weeks (18%) prior to gastrostomy tube placement, but the temporal relationship between shunt and gastrostomy was not a significant predictor of shunt infection.CONCLUSIONSGastrostomy tube placement significantly increases the risk of ventriculoperitoneal shunt infection.
A Decision Analysis of Observation vs Immediate Reintervention for Asymptomatic Residual Fragments Less than 4 mm Following Ureteroscopic Lithotripsy
Ursiny, Michal, Yaghoubian, Alan J., Humphreys, Mitchell R. , Brotherhood, Hilary, Chew, Benjamin, Monga, Manoj, Krambeck, Amy E. , Charchenko, Cameron, Wang, An Qi, Sur, Roger L. , Miller, Nicole L. , Marien, Tracy , Chang, Yui-Hui H., Knudsen, Bodo E. , Lange, Dirk , Yong, Courtney , Matlaga, Brian R., Shah, Ojas , Pais, Vernon M., Lipkin, Michael E. , Eisner, Brian H. , Miller, Nicole L

Mayo Clinic

Urology Practice | February 4, 2019 | Volume: 6 | Issue: 5 | Pages: 294-299

10.1097/upj.0000000000000038 | PMID 37317352 Get It

Genes associated with serum estrone, estrone conjugates, and androstenedione concentrations in postmenopausal women with estrogen receptor-positive breast cancer.
Dudenkov, Tanda M., Buzdar, Aman U. , Kubo, Michiaki , Batzler, Anthony , Jenkins, Gregory D. , Pietrzak, Tracy L., Northfelt, Donald W. , Perez, Edith A. , Williard, Clark, Nakamura, Yusuke , Wang, Liewei , Weinshilboum, Richard M. , Ingle, James N. , Robson, Mark E. , Carlson, Erin E. , Fridley, Brooke L. , Goetz, Matthew P. , Kalari, Krishna R. , Weinshilboum, Richard M.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 593-593

10.1200/jco.2014.32.15_suppl.593 Get It

Characterization of genomic alterations and biomarker expression patterns of gastrointestinal cancers using a multiplatform molecular profiling tool.
Vélez, Miguel González , McKenna, Marshall, Duma, Narjust , Krishnasamy, Shalini, Proverbs‐Singh, Tracy, Gutierrez, Martin , Suero‐Abreu, Giselle Alexandra

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 594-594

10.1200/jco.2018.36.4_suppl.594 Get It

594 Background: Given the heterogeneity of gastrointestinal cancers (GICs), molecular profiling is becoming part of the standard of care for many solid tumors. The aim of this study was to evaluate the molecular profile of patients (pts) with GICs using a multiplatform profiling tool and to assess how the pattern of detected molecular alterations could guide clinical decision-making in these tumors. Methods: We retrospectively analyzed samples of 85 pts with GICs via a multiplatform profiling service (Caris Life Sciences, Phoenix, AZ) in order to evaluate clinically relevant genomic alterations (CRGAs) and clinically relevant biomarker expression (CRBs) in GICs. Results: A total of 85 pts with GICs were analyzed. 45 (53 %) were males and 40 (47%) were females. Tumors were colorectal 43 (51%), pancreatic 11 (13%) esophageal 11 (13%) gastric 8 (9%), hepatobiliary 8 (11%), anal canal 3 (4%), and small intestine 1 (1%). 80 cases (94%) had adequate sample for profiling. CRGAs were identified in 71 cases (89%) with a median of 3 CRGAs in the cohort. The most commonly detected CRGAs were TP53 45 (56%), APC 35 (44%), KRAS 32 (40%), ATM 14 (18%) and PTEN 5 (6%). The median number of CRBs was 9 and high expression levels were seen of mismatch repair biomarkers (MLH1, MSH2, MSH6, PMS2) in 45 (56%), TOPO1 in 44 (55%), PTEN in 27 (34%), TOP2A in 20 (25%), ERCC1 in 19 (24%), and both TS and TUBB3 in 17 (21%). Based on actionable CRGAs and CRBs, 94% of pts matched at least one FDA approved treatment with proven clinical benefit, with a median of 4 available therapies per pt. In addition, there was a median of 189 chemotherapy and 64 targeted therapy clinical trial opportunities available for these pts given the molecular blueprint of their GICs. Conclusions: Multiplatform molecular profiling identified a high frequency of actionable CRGAs and CRBs in GIC pts. This approach has the potential to aid in clinical decision-making by providing a stratification of beneficial therapeutic alternatives individualized to the molecular framework of tumor. Larger prospective studies are warranted to further investigate the impact of profiling guided treatment decisions on patient outcomes.
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Mandrekar, Sumithra J. , Laumann, Kristina, Walker, Alison R. , Wang, Eunice S. , Kolitz, Jonathan E. , Powell, Bayard L., Attar, Eyal C. , Bloomfield, Clara D. , Kohlschmidt, Jessica, Mrózek, Krzysztof , Garraway, Levi A. , Jané‐Valbuena, Judit , Baltay, Michele , Tracy, Adam , Marcucci, Guido , Stone, Richard M. , Wang, Eunice S. , Roboz, Gail J. , Desai, Pinkal , Stock, Wendy , Hassane, Duane C. , Larson, Richard A.

Mayo Clinic

Blood Advances | December 19, 2018 | Volume: 2 | Issue: 24 | Pages: 3608-3617

10.1182/bloodadvances.2018023689 | PMID 30567725 Get It

Abstract Novel treatment strategies are needed for older patients with acute myeloid leukemia (AML). This randomized phase 2 trial compared the efficacy and safety of 20 mg/m2 of IV decitabine on days 1 to 10 alone (arm A) with those of 1.3 mg/m2 of subcutaneous bortezomib (arm B) on days 1, 4, 8, and 11 for up to 4 10-day cycles followed by monthly 5-day cycles. Previously untreated AML patients age ≥60 years (excluding those with FLT3 mutations and favorable-risk cytogenetics) without restrictions in performance status (PS) or organ function were eligible. Median age was 72.4 years (range, 60.5-92.3 years); 31 patients (19%) had baseline PS ≥2, 35 (22%) had an antecedent hematological disorder, 58 had (39%) adverse cytogenetics, and 7 (5%) and 23 (14%) had abnormal cardiac or renal function. There were no statistically significant differences in overall survival (OS) or responses between the 2 treatment arms. The overall response rate (complete remission + complete remission with incomplete blood count recovery) was 39% (n = 64), with median OS of 9.3 months. Nineteen responders (31%) underwent allogeneic stem cell transplantation. The most common adverse event was febrile neutropenia, and there were no unexpected toxicities. Adding bortezomib to decitabine did not improve outcomes, but responses were better than those in previous trials using 5-day decitabine cycles. This trial was registered at www.clinicaltrials.gov as #NCT01420926.
RUNX1‐dependent mechanisms in biological control and dysregulation in cancer
Hong, Deli , Fritz, Andrew J. , Gordon, Jonathan A. R., Tracy, Kirsten M. , Frietze, Seth , Carr, Frances E. , Nickerson, Jeffrey A. , Wijnen, André J. van , Imbalzano, Anthony N. , Zaidi, Sayyed K. , Lian, Jane B. , Stein, Janet L. , Tracy, Kirsten M , van Wijnen, Andre J , Stein, Gary S , Tye, Coralee E. , Boyd, Joseph R. , Stein, Gary S.

Mayo Clinic

Journal of Cellular Physiology | December 5, 2018 | Volume: 234 | Issue: 6 | Pages: 8597-8609

10.1002/jcp.27841 | PMID 30515788 Get It

AbstractThe RUNX1 transcription factor has recently been shown to be obligatory for normal development. RUNX1 controls the expression of genes essential for proper development in many cell lineages and tissues including blood, bone, cartilage, hair follicles, and mammary glands. Compromised RUNX1 regulation is associated with many cancers. In this review, we highlight evidence for RUNX1 control in both invertebrate and mammalian development and recent novel findings of perturbed RUNX1 control in breast cancer that has implications for other solid tumors. As RUNX1 is essential for definitive hematopoiesis, RUNX1 mutations in hematopoietic lineage cells have been implicated in the etiology of several leukemias. Studies of solid tumors have revealed a context‐dependent function for RUNX1 either as an oncogene or a tumor suppressor. These RUNX1 functions have been reported for breast, prostate, lung, and skin cancers that are related to cancer subtypes and different stages of tumor development. Growing evidence suggests that RUNX1 suppresses aggressiveness in most breast cancer subtypes particularly in the early stage of tumorigenesis. Several studies have identified RUNX1 suppression of the breast cancer epithelial‐to‐mesenchymal transition. Most recently, RUNX1 repression of cancer stem cells and tumorsphere formation was reported for breast cancer. It is anticipated that these new discoveries of the context‐dependent diversity of RUNX1 functions will lead to innovative therapeutic strategies for the intervention of cancer and other abnormalities of normal tissues.
Influence of Cardiovascular Risk Communication Tools and Presentation Formats on Patient Perceptions and Preferences
Wang, Tracy Y , Mi, Xiaojuan, Robinson, Jennifer G. , Roger, Véronique L. , Goldberg, Anne C. , Návar, Ann Marie , Virani, Salim S. , Wilson, Peter W.F. , Peterson, Eric D.

Mayo Clinic

JAMA Cardiology | November 12, 2018 | Volume: 3 | Issue: 12 | Pages: 1192

10.1001/jamacardio.2018.3680 | PMID 30419113 Get It

Introduction of novel agents in the treatment of primary CNS lymphoma
Grommes, Christian , Nayak, Lakshmi , Batchelor, Tracy T. , Tun, Han W.

Mayo Clinic

Neuro-Oncology | November 12, 2018 | Volume: 21 | Issue: 3 | Pages: 306-313

10.1093/neuonc/noy193 | PMID 30423172 Get It

A tropomyosin-receptor kinase-fused gene mutation associates with vacuolar myopathy
Madigan, Nicolas N. , Tracy, Jennifer A., Litchy, William J. , Niu, Zhiyv , Chen, Chunhua , Ling, Kun , Milone, Margherita , Niu, Zhiyv

Mayo Clinic

Neurology Genetics | November 7, 2018 | Volume: 4 | Issue: 6 | Pages: No page available

10.1212/nxg.0000000000000287 | PMID 30643850 Get It

Assessment and Management of Patients With Metastatic Spinal Cord Compression: A Multidisciplinary Review
Lawton, Andrew J. , Lee, Kathleen A., Ferrone, Marco , Rades, Dirk , Abrahm, Janet L. , Cheville, Andrea , Balboni, Tracy Anne

Mayo Clinic

Journal of Clinical Oncology | November 5, 2018 | Volume: 37 | Issue: 1 | Pages: 61-71

10.1200/jco.2018.78.1211 | PMID 30395488 Get It

PurposeMetastatic spinal cord compression (MSCC) can be a catastrophic manifestation of advanced cancer that causes immobilizing pain and significant neurologic impairment. Oncologists can protect their patients by having a high index of suspicion for MSCC when patients present with new or worsening back pain before motor, sensory, bowel, or bladder deficits develop. We provide an updated, evidence-based narrative review of the presentation, diagnosis, and treatment of MSCC.MethodsThis narrative review was conducted by searching MEDLINE and Cochrane Database of Systematic Reviews for relevant literature on the presentation, diagnosis, and treatment of patients with MSCC. The article addresses the key elements of MSCC management germane to the medical oncologist, with special attention given to pain and symptom management, decision making with regard to surgery and radiation therapy, the importance of rehabilitative care, and the value of a multidisciplinary approach.ResultsMagnetic resonance imaging of the entire spine is recommended for the diagnosis of MSCC. Treatment includes glucocorticoid therapy, pain management, radiation therapy with or without surgery, and specialized rehabilitation. When formulating a treatment plan, clinicians should consider the patient’s care goals and psychosocial needs.ConclusionPrompt diagnosis and treatment of MSCC can reduce pain and prevent irreversible functional loss. Regular collaboration among multidisciplinary providers may streamline care and enhance achievement of treatment goals.